Brean Murray Initiates Coverage on Obagi Medical Products (OMPI) with Buy
OMPI Hot Sheet
Rating Summary:2 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
Brean Murray initiates coverage on Obagi Medical Products (Nasdaq: OMPI) with Buy. Price target $10
Brean analyst says, "The stock, along with the perception of the company's near-term prospects, has been battered by the economic downturn. Nevertheless, we believe that the company's market-leading brand and customer base, its products' synergies with other aesthetic products like Botox and laser therapy, and its potential as an acquisition, make the risk/reward proposition compelling at these levels."
Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets.
Brean analyst says, "The stock, along with the perception of the company's near-term prospects, has been battered by the economic downturn. Nevertheless, we believe that the company's market-leading brand and customer base, its products' synergies with other aesthetic products like Botox and laser therapy, and its potential as an acquisition, make the risk/reward proposition compelling at these levels."
Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
